Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers

Vaccine

Volumn 21, Issue 27-30, 2003, Pages 4256-4260

  Kawana, Kei ^a   Yasugi, Toshiharu ^a   Kanda, Tadahito ^b   Kino, Nao ^a   Oda, Katsutoshi ^a   Okada, Satoshi ^a   Kawana, Yukiko ^a   Nei, Tomomi ^a   Takada, Toshio ^a   Toyoshima, Sosuke ^a   Tsuchiya, Akira ^a   Kondo, Kazunari ^b,c   Yoshikawa, Hiroyuki ^c   Tsutsumi, Osamu ^a   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

HPV; L2 peptide; Prophylactic broad spectrum vaccine

Indexed keywords

ANTIBODY; EPITOPE; PEPTIDE; PLACEBO;

ADULT; ANTIGEN BINDING; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEALTH STATUS; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INOCULATION; MALAISE; MALE; PRIORITY JOURNAL; RECIPIENT; RHINORRHEA; SEROLOGY; SERUM; SIDE EFFECT; SNEEZING; VERRUCA VULGARIS; VIRUS CAPSID; VOLUNTEER;

EID: 10744232843     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00454-7     Document Type: Article

References (15)

1. Pisani P., Parkin D.M., Bray F., Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer. 83:1999;18-29.
2. Harro C.D., Pang Y.Y., Roden R.B.et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:2001;284-292.
3. Evans T.G., Bonnez W., Rose R.C.et al. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183:2001;1485-1493.
4. Koutsky L.A., Ault K.A., Wheeler C.M.et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:2002;1645-1651.
5. Roden R.B., Yutzy W.H. 4th, Fallon R., Inglis S., Lowy D.R., Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 270:2000;254-257.
6. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Common neutralizing epitope in minor capsid protein L2 of human papillomavirus type 16 and 6. J. Virol. 73:1999;6188-6190.
7. Kawana Y., Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J. Virol. 75:2001;2331-2336.
8. Kawana K., Kawana Y., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine. 19:2001;1496-1502.
9. Embers M.E., Budgeon L.R., Pickel M., Christensen N.D. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. 76:2002;9798-9805.
10. Lycke N. T cell and cytokine regulation of the IgA response: chemical immunology. In: Mucosal T cell, vol. 71. New York: Karger; 1998. p. 209-34.
11. Matsumoto K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn. J. Cancer Res. 88:1997;369-375.
12. Matsumoto K., Yoshikawa H., Yasugi T.et al. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan. J. Med. Virol. 69:2003;441-446.
13. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J. Virol. 72:1998;10298-10300.
14. Kozlowski P.A., Williams S.B., Lynch R.M.et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 169:2002;566-574.
15. Yang R., Day P.M., Yutzy W.H., Lin K.Y., Hung C.F., Roden R.B.S. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J. Virol. 77:2003;3531-3541.